Search

Your search keyword '"Amélie Steinhoff"' showing total 2 results
Start Over Author "Amélie Steinhoff"
2 results on '"Amélie Steinhoff"'

1. Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer

Author

Doris Höflmayer, Amélie Steinhoff, Claudia Hube‐Magg, Martina Kluth, Ronald Simon, Eike Burandt, Maria Christina Tsourlakis, Sarah Minner, Guido Sauter, Franziska Büscheck, Waldemar Wilczak, Stefan Steurer, Hartwig Huland, Markus Graefen, Alexander Haese, Hans Heinzer, Thorsten Schlomm, Frank Jacobsen, Andrea Hinsch, Alexandra M. Poos, Marcus Oswald, Karsten Rippe, Rainer König, and Cornelia Schroeder

Subjects
CTCF, deletion, prostate cancer, TMA, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The chromatin‐organizing factor CCCTC‐binding factor (CTCF) is involved in transcriptional regulation, DNA‐loop formation, and telomere maintenance. To evaluate the clinical impact of CTCF in prostate cancer, we analyzed CTCF expression by immunohistochemistry on a tissue microarray containing 17 747 prostate cancers. Normal prostate tissue showed negative to low CTCF expression, while in prostate cancers, CTCF expression was seen in 7726 of our 12 555 (61.5%) tumors and was considered low in 44.6% and high in 17% of cancers. Particularly, high CTCF expression was significantly associated with the presence of the transmembrane protease, serine 2:ETS‐related gene fusion: Only 10% of ERG‐negative cancers, but 30% of ERG‐positive cancers had high‐level CTCF expression (P

Published
2020
Full Text
View/download PDF

2. Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer

Author

Alexander Haese, Maria Christina Tsourlakis, Thorsten Schlomm, Eike Burandt, Franziska Büscheck, Guido Sauter, Hartwig Huland, Claudia Hube-Magg, Marcus Oswald, Frank Jacobsen, Waldemar Wilczak, Amélie Steinhoff, Rainer König, Sarah Minner, Stefan Steurer, Doris Höflmayer, Cornelia Schroeder, Hans Heinzer, Alexandra M Poos, Karsten Rippe, Markus Graefen, Andrea Hinsch, Martina Kluth, and Ronald Simon

Subjects
Male, 0301 basic medicine, CCCTC-Binding Factor, Cancer Research, Oncogene Proteins, Fusion, Fusion gene, Prostate cancer, 0302 clinical medicine, Prostate, Medicine, deletion, Research Articles, Sequence Deletion, Tissue microarray, Serine Endopeptidases, General Medicine, Middle Aged, Prognosis, prostate cancer, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunohistochemistry, Gene Expression Regulation, Neoplastic, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Molecular Medicine, Biomarker (medicine), Research Article, Biochemical recurrence, lcsh:RC254-282, 03 medical and health sciences, Transcriptional Regulator ERG, Biomarkers, Tumor, Genetics, Humans, TMA, Aged, Cell Proliferation, business.industry, Prostatic Neoplasms, CTCF, medicine.disease, Ki-67 Antigen, 030104 developmental biology, Tissue Array Analysis, Cancer research, Neoplasm Grading, business
Abstract

The chromatin‐organizing factor CCCTC‐binding factor (CTCF) is involved in transcriptional regulation, DNA‐loop formation, and telomere maintenance. To evaluate the clinical impact of CTCF in prostate cancer, we analyzed CTCF expression by immunohistochemistry on a tissue microarray containing 17 747 prostate cancers. Normal prostate tissue showed negative to low CTCF expression, while in prostate cancers, CTCF expression was seen in 7726 of our 12 555 (61.5%) tumors and was considered low in 44.6% and high in 17% of cancers. Particularly, high CTCF expression was significantly associated with the presence of the transmembrane protease, serine 2:ETS‐related gene fusion: Only 10% of ERG‐negative cancers, but 30% of ERG‐positive cancers had high‐level CTCF expression (P, The transcriptional repressor CCCTC‐binding factor, which is involved in modeling the chromatin face in the nucleus of a cell, was analyzed for its expression in prostate cancer. We report here that its upregulation was associated with a shorter prostate‐specific antigen recurrence‐free survival after prostatectomy in a large cohort of prostate cancer patients.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results